Analysts at StockNews.com initiated coverage on shares of NanoViricides (NYSE:NNVC – Get Free Report) in a research report issued on Thursday. The brokerage set a “sell” rating on the stock.
NanoViricides Trading Up 20.5 %
NYSE:NNVC opened at $2.03 on Thursday. The stock has a fifty day moving average price of $1.22 and a 200 day moving average price of $1.17. NanoViricides has a 12-month low of $1.00 and a 12-month high of $2.07. The firm has a market cap of $23.85 million, a PE ratio of -2.50 and a beta of 0.70.
NanoViricides (NYSE:NNVC – Get Free Report) last announced its quarterly earnings data on Wednesday, February 14th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01.
NanoViricides Company Profile
NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.
Further Reading
- Five stocks we like better than NanoViricides
- What is a Death Cross in Stocks?
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Generac Powers Ahead on the Electrification Mega-Trend
- 3 Best Fintech Stocks for a Portfolio Boost
- PulteGroup Wins and Wins More on Interest Rate Cuts
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.
